Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Enlaza's War-Lock platform uses covalent-acting protein drugs with non-natural amino acids, enhancing therapeutic windows for safer, effective treatments. The partnership targets autoimmune diseases ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 6.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

People don't like online forms (gasp!). And it's not hard to see why: Online forms require extra work (and time) and typically stand in the way of a consumer's getting what he or she really wants—such ...

Excel’s new AI feature simplifies word-to-number conversions, transforming data handling for professionals across industries.

Threads is testing a new feature that makes it easy to share long-form text on the social network, Meta confirmed to TechCrunch on Thursday. The feature lets users attach a block of text to a post ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...

Corrections and clarifications: This story has been updated to clarify which company owns Smokey Bones. Restaurant and bar Smokey Bones is welcoming new leadership and closing more stores due to ...

The Staunton-Augusta-Waynesboro region is testing a new P25 Digital Trunked radio system for public safety personnel. This $15 million upgrade will improve radio coverage, eliminate dead spots, and ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...